2026-05-08FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinomaDrug Bizengri (zenocutuzumab-zbco) · Anti-HER2-HER3 bispecific antibodyConditionGastrointestinal
2024-12-04FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinomaDrug Bizengri (zenocutuzumab-zbco) · Anti-HER2-HER3 bispecific antibodyConditionsGastrointestinalThoracic